David R. Deyle

David R. Deyle, M.D., is an Associate Professor of Medical Genetics at Mayo Clinic in Rochester, Minnesota. He holds primary and joint appointments as a Consultant in the Department of Medical Genetics, Department of Molecular Medicine, Department of Cardiovascular Medicine, Department of Orthopedic Surgery, and Department of Pediatric and Adolescent Medicine. His multidisciplinary role reflects his integrative research in gene and cell therapy for genetic disorders.

Dr. Deyle earned his M.D. from the University of Minnesota Medical School, completed residency in Internal Medicine and Pediatrics at the University of Minnesota, and underwent fellowship training in Medical Genetics at the University of Washington, Seattle. He is board-certified in Clinical Genetics and Genomics by the American Board of Medical Genetics and Genomics.

His research focuses on developing gene and cell therapies through genomic editing in human stem cells. Key areas include treating osteogenesis imperfecta using iPSCs and AAV vectors, in vivo modeling of skeletal diseases, and oncolytic measles virus (MV-NIS) therapy for neurofibromatosis 1 (NF1) tumors. His work leverages CRISPR, TALENs, and adeno-associated virus (AAV) technologies to precisely modify the genome in mesenchymal and induced pluripotent stem cells for regenerative medicine applications.

Analysis of his recent publications reveals a strong trend in clinical genomics, stem cell engineering, and translational gene therapy. His work spans rare genetic disorders such as Ehlers-Danlos syndrome, achondroplasia, and mucopolysaccharidosis, with a consistent emphasis on improving diagnostic and therapeutic pipelines through genomic innovation.

• Discovery Science Award, Regenerative Medicine Minnesota (2020–2022)
• Gene Therapy of Arthritis and Related Disorders Young Investigator Award (2008)
• NIH Loan Repayment Program Grant (2006)
• Summa Cum Laude, University of Minnesota (1993)

Dr. Deyle has served as Principal Investigator on multiple NIH-funded grants, including projects on in vivo gene targeting for inherited bone disease and engineering pluripotent stem cells for osteogenesis imperfecta. He has also been a mentor and committee member in the American Society of Gene & Cell Therapy and has reviewed grants for NIH study sections (NIAMS, NINDS, NCMRR). His laboratory is part of the Center for Individualized Medicine and the Center for Regenerative Biotherapeutics at Mayo Clinic, where his team develops preclinical models and novel viral vector systems for genetic correction.